This webinar covered
Since January 2023, the RNA and Gene Therapy landscapes have been nothing but dynamic. Overall, 21 drugs entered the clinic for the first time, 9 preclinical and 9 clinical drugs were discontinued, and 2 drugs (VYJUVEK and Elevidys) were approved within the gene therapy space, while there have been 79 therapies entering the clinic across the mRNA, oligonucleotide, and gene editing space.
Navigating these quickly evolving landscapes makes access to accurate and comprehensive information paramount to informed decision-making. Therefore, to conclude our landscape review series, and to explore the array of data available across the RNA and Gene Therapy landscapes, our research experts explored the drug and trial report data across both modalities and provide further exclusive insights. Key aspects included:
- A mid-year review of the RNA landscape, focusing on messenger RNAs, oligonucleotides, and guide RNA-mediated gene editing
- An exploration of the current Gene Therapy drug and trial landscape, covering the 2000+ drugs and the 800+ trials tracked on Beacon
- A picture of what we can likely expect ahead based on recent approvals and late-stage activity
Hosted by
Webinar Leaders
House Speaker
House Speaker
Moderator
Speak with our team about Beacon RNA and Beacon Gene Therapy
What is Beacon RNA?
Beacon RNA is a manually curated database solution that includes clinical trial and drug data for preclinical, active, approved, and discontinued:
- Oligonucleotide-based therapies
- mRNA-Based Therapies
- Ribozyme Therapies
- gRNA-Mediated Gene Editing Therapies
- RNA-Targeted Small Molecules
Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
What is Beacon Gene Therapy?
Beacon Gene Therapy is a manually curated database solution that includes clinical trial and drug records for preclinical, active, approved, and discontinued:
- RNA/DNA Viral vector based therapies
- DNA Non-viral vector based therapies
- Genetically Modified cell therapies
- Empty Vector Trials
- Other comparable modalities within gene therapy whether cell-free or cell-based
- Beacon Gene Therapy covers all genetically driven non-oncology indications that utilize gene therapy to mediate the condition.
How Beacon RNA and Beacon Gene Therapy works
Search the RNA trial and drug landscape by target organ, formulation, nucleic acid modification, editing technology.
Search the Gene Therapy clinical trial and drug landscape by promoter, target organ/cell, or gene delivery system, etc, instantaneously and/or extract the data points you need to conduct more complex analysis.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely, and exhaustive single-drug timeline allowing you to benchmark progress in the RNA and Gene Therapy space.
How we target the data
We house all publicly available sources of data updated within 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
- Patents
What is Beacon?
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
